Stem cell therapy for acute myocardial infarction: MSCs and iPscs.
Diana ClavellinaWayne BalkanJoshua M HarePublished in: Expert opinion on biological therapy (2023)
MSCs show undeniable promise for treating AMI, but addressing their low survival and engraftment rates is crucial for clinical success. Integrating emerging technologies and well-designed trials will harness MSC therapy's full potential in AMI management. Collaborative efforts are vital to developing effective stem cell therapies for AMI patients.
Keyphrases
- acute myocardial infarction
- stem cells
- percutaneous coronary intervention
- end stage renal disease
- mesenchymal stem cells
- left ventricular
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- quality improvement
- acute coronary syndrome
- prognostic factors
- cell therapy
- heart failure
- human health
- bone marrow
- hematopoietic stem cell